Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Malignant Melanoma

Interventions: Drug: Drug cocktail
Drug: RO5185426

First Posted Date: 2009-10-26

Last Posted Date: 2017-08-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 25

Registration Number: NCT01001299

Locations: 🇺🇸
UCLA - School of Medicine, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital;Hematology/ Oncology, Boston, Massachusetts, United States
🇺🇸
Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States

and more 2 locations

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: rituximab [MabThera/Rituxan]
Drug: methotrexate
Drug: methylprednisolone

First Posted Date: 2009-10-23

Last Posted Date: 2017-08-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 18

Registration Number: NCT01000610

Locations: 🇹🇳
Hopital Farhat Hached; Service Rhumatologie, Sousse, Tunisia
🇹🇳
Hopital La Rabta; Service Rhumatologie, Tunis, Tunisia
🇹🇳
Hopital Charles Nicole; Service Rhumatologie, Tunis, Tunisia

and more 1 locations

A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: tocilizumab [RoActemra/Actemra]
Drug: DMARDs (disease-modifying antirheumatic drugs)

First Posted Date: 2009-10-16

Last Posted Date: 2018-03-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 201

Registration Number: NCT00996203

Locations: 🇷🇺
Sverdlovsk Regional Clinical Hospital # 1; Rheumatology Dept, Ekaterinburg, Russian Federation
🇷🇺
Republican Clinicodiagnostic Center, Izhevsk, Russian Federation
🇷🇺
Kaliningrad Regional Clinical Hospital; Rheumatologic Department, Kaliningrad, Russian Federation

and more 25 locations

A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: DMARDs
Drug: Tocilizumab

First Posted Date: 2009-10-16

Last Posted Date: 2017-06-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 58

Registration Number: NCT00996606

A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis

Phase 3

Completed

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: Tocilizumab
Drug: Placebo

First Posted Date: 2009-10-02

Last Posted Date: 2017-07-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 188

Registration Number: NCT00988221

Locations: 🇦🇺
Princess Margaret Children'S Hospital; Department of Immunology, Subiaco, Western Australia, Australia
🇨🇦
Alberta Children'S Hospital, Calgary, Alberta, Canada
🇨🇦
Children'S Hospital of Eastern Ontario, Ottawa, Ontario, Canada

and more 66 locations

A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection

Phase 1

Completed

Conditions: Influenza

Interventions: Drug: Tamiflu

First Posted Date: 2009-10-02

Last Posted Date: 2017-03-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 65

Registration Number: NCT00988325

Locations: 🇩🇪
Onkologische Schwerpunktpraxis Dr. Med. O. Burkhard & B. Reimann, Worms, Germany
🇮🇹
Fondazione Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
🇵🇱
Vitamed, Bydgoszcz, Poland

and more 9 locations

A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: RAD001
Drug: RG1507

First Posted Date: 2009-09-28

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 11

Registration Number: NCT00985374

Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

Phase 2

Completed

Conditions: HCV Infection

Interventions: Drug: ANA598
Drug: placebo
Drug: Peginterferon
Drug: Ribavirin

First Posted Date: 2009-09-17

Last Posted Date: 2017-03-31

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 97

Registration Number: NCT00978497

Locations: 🇺🇸
United States, New York, New York, New York, United States
🇺🇸
United States, Maryland, Lutherville, Maryland, United States
🇺🇸
United States, California 2, San Clemente, California, United States

and more 17 locations

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Phase 3

Completed

Conditions: Ovarian Cancer

Interventions: Drug: liposomal doxorubicin
Drug: Bevacizumab
Drug: paclitaxel
Drug: topotecan

First Posted Date: 2009-09-15

Last Posted Date: 2022-06-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 361

Registration Number: NCT00976911

Locations: 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇩🇪
Klinikum Nord Frauenklinik, Nürnberg, Germany
🇧🇪
UZ Antwerpen, Edegem, Belgium

and more 114 locations

A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Pertuzumab
Drug: TCH
Drug: Trastuzumab
Drug: FEC
Drug: Docetaxel

First Posted Date: 2009-09-15

Last Posted Date: 2017-02-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 225

Registration Number: NCT00976989

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy